AT501

zCAR-T treatment for HER2-positive ovarian cancer

AT501 is a type of immunotherapy developed using zCAR-T technology for the treatment of ovarian cancer expressing HER2. zCAR-T’s activity can be modulated in vivo via the use of a switch molecule

Ovarian cancer has a high cure rate when detected at an early stage. However in late stage
ovarian cancer, when cancer cells begin to metastasize to the abdominal cavity, the prognosis
is less optimistic. Since ovarian cancer patients only develop symptoms in the latter stages
of the disease, a more effective treatment for late-stage ovarian cancer patients is needed.
AT501 (zCAR-T treatment) specifically targets HER2-expressing disease proteins of ovarian
cancer and can even suppress it from metastasizing.